Amneal Pharmaceuticals (NYSE:AMRX) Updates FY22 Earnings Guidance

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) issued an update on its FY22 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.80-0.85 for the period, compared to the Thomson Reuters consensus estimate of $0.84. The company issued revenue guidance of $2.15-2.25 billion, compared to the consensus revenue estimate of $2.19 billion.

Shares of AMRX stock opened at $4.01 on Wednesday. Amneal Pharmaceuticals has a twelve month low of $3.76 and a twelve month high of $6.21. The stock has a market cap of $1.21 billion, a P/E ratio of 44.56, a P/E/G ratio of 0.22 and a beta of 1.24. The stock has a 50 day moving average of $4.13 and a 200 day moving average of $4.53. The company has a current ratio of 2.35, a quick ratio of 1.57 and a debt-to-equity ratio of 7.11.

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Amneal Pharmaceuticals had a net margin of 0.68% and a return on equity of 61.08%. The business had revenue of $497.30 million for the quarter, compared to analysts’ expectations of $502.29 million. During the same quarter last year, the company earned $0.19 EPS. The business’s revenue was up .9% on a year-over-year basis. On average, research analysts predict that Amneal Pharmaceuticals will post 0.8 earnings per share for the current fiscal year.

A number of brokerages have weighed in on AMRX. Barclays decreased their price objective on shares of Amneal Pharmaceuticals from $8.00 to $7.00 in a research report on Thursday, April 28th. Zacks Investment Research raised Amneal Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday.

Institutional investors have recently bought and sold shares of the company. LPL Financial LLC increased its position in shares of Amneal Pharmaceuticals by 18.4% in the third quarter. LPL Financial LLC now owns 38,628 shares of the company’s stock valued at $206,000 after buying an additional 6,006 shares in the last quarter. Royal Bank of Canada increased its position in shares of Amneal Pharmaceuticals by 8.2% in the third quarter. Royal Bank of Canada now owns 52,999 shares of the company’s stock valued at $283,000 after buying an additional 3,995 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Amneal Pharmaceuticals by 67.0% in the third quarter. BNP Paribas Arbitrage SA now owns 61,700 shares of the company’s stock worth $329,000 after acquiring an additional 24,756 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Amneal Pharmaceuticals by 54.2% in the fourth quarter. Bank of America Corp DE now owns 62,962 shares of the company’s stock worth $302,000 after acquiring an additional 22,134 shares during the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of Amneal Pharmaceuticals by 341.9% in the fourth quarter. Stifel Financial Corp now owns 87,780 shares of the company’s stock worth $420,000 after acquiring an additional 67,917 shares during the last quarter. Institutional investors and hedge funds own 38.54% of the company’s stock.

About Amneal Pharmaceuticals (Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Featured Stories

Earnings History and Estimates for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.